Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_2
6
100%

Phase Distribution

0

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
6(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(1)
Other(2)

Detailed Status

Completed3
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 26 (100.0%)

Trials by Status

completed350%
terminated117%
unknown233%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

NCT04326257
terminatedphase_2

Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

NCT04203901
completedphase_2

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

NCT02917772
unknownphase_2

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

NCT03219775
completedphase_2

SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

NCT03065179
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04326257Phase 2

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Completed
NCT04203901Phase 2

Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

Terminated
NCT02917772Phase 2

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

Completed
NCT03219775Phase 2

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma

Unknown
NCT03065179Phase 2

SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients

Completed
NCT04131621Phase 2

Nivolumab/Ipilimumab in Second Line CUP-syndrome

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6